

MONDAY, MAY 27, 2024 ORAL ABSTRACTS AND POSTERS

Poster ID (submission ID)		
	DIAGNOSIS OF AMYLOID	
OA1 (#496)	A feasibility study into computer vision quantification of cardiac amyloid burden in endomyocardial biopsies	Taxiarchis Kourelis Mayo Clinic
OA2 (#99)	AmyLite Assay Quantifies Kinetically Unstable Circulating Amyloidogenic Lambda FLC – Diagnostic and Prognostic Implications for Lambda AL Amyloidosis	Xin Jiang Protego Biopharma
OA3 (#420)	Lumbar spinal stenosis (LSS) and carpal tunnel syndrome (CTS) as surrogates for wild-type transthyretin amyloid cardiomyopathy (ATTR-CM)	Laura De Michieli Universita degli Studi di Padova
OA4 (#564)	Screening for Amyloidosis at the time of Carpal Tunnel Release Surgery in Real World Practice is a Successful Strategy at Diagnosing Early Cardiac Amyloidosis	Mazen Hanna Cleveland Clinic
	BASIC SCIENCE AL AMYLOIDOSIS	
OA5 (#464)	Bone marrow-free sequencing of M protein genes: a liquid biopsy approach in monoclonal gammopathies	Alice Nevone Regione Lombardia
OA6 (#253)	Characterization of the Peptide-Antibody Fusion, AT-02 – Studies to Support its Use as an Immunotherapy in Patients with Amyloidosis	Jonathan Wall University of Tennessee
OA7 (#38)	Helical superstructures between amyloid and collagen VI in heart-derived fibrils from a patient with Light Chain Amyloidosis.	Stefano Ricagno Universita degli Studi di Milano
OA8 (#181)	Patient derived AL amyloid induces cellular toxicity in macrophages, hepatocytes, and cardiomyocytes upon cellular engulfment of amyloid material	Joseph Jackson The University of Tennessee System
OA9 (#333)	Single-cell, spatial analysis of the renal AL immunome supports a T-cell mediated tissue toxicity mechanism.	Charalampos Charalampous Mayo Clinic
	AL AMYLOIDOSIS PROGNOSIS AND TREATMENT	
OA10 (#466)	A phase II study of daratumumab and pomalidomide in previously treated patients with AL amyloidosis	Paolo Milani Universita degli Studi di Pavia
OA11 (#209)	Clinical Factors Associated with Early Sudden Unexpected Death in Systemic AL Amyloidosis: Insights from 138 Cases	Andrew Staron Boston Medical Center
OA12 (#267)	An ECG-Echo Risk Score for Systemic Light Chain Amyloidosis	Aparna Hari Mata Amritanandamayi Math
OA13 (#529)	Daratumumab-Based Front-line Therapy Improves Treatment Response and Survival in Patients with Immunoglobulin Light chain (AL) Amyloidosis: The Mayo Clinic Experience	Binoy Yohannan Mayo Clinic
OA14 (#185)	Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light-Chain Amyloidosis: A Phase 2 Study by the European Myeloma Network	Efstathios Kastritis Ethniko kai Kapodistriako Panepistemio Athenon

MONDAY, MAY 27, 2024 ORAL ABSTRACTS AND POSTERS

OA15 (#273)	Ethnicity in AL amyloidosis shows underestimation of disease risks by biomarker-based staging for ethnic minorities patients in systemic AL amyloidosis	Jahanzaib Khwaja HM Government of the UK of Great Britain and Northern Ireland
OA16 (#501)	Outcomes of patients with AL amyloidosis and end-stage renal disease after initiation of therapy	Efstathios Kastritis Ethniko kai Kapodistriako Panepistemio Athenon
OA17 (#264)	Peripheral Neuropathy in AL Amyloidosis: Clinical Presentations and Outcomes of Current Therapies	Pitcha Chompoonpong Regents of the University of Minnesota
OA18 (#235)	Plasma cell characteristics predict benefit from intensified therapy in AL amyloidosis	Maximilian Steinhardt Julius-Maximilians-Universitat Wurzburg
OA19 (#475)	Proposed hematologic progression criterion in patients with AL amyloidosis.	Giovanni Palladini Universita degli Studi di Pavia

AI/ELECTRONIC RECORDS TO FACILITATE DIAGNOSIS

PA1 (#12)	A Qualitative Study of Artificial Intelligence-Based Tools to Raise Suspicion for ATTR Cardiomyopathy	Baljash Cheema Northwestern University
PA2 (#69)	Machine Learning-Based Clustering Identifies Novel Subgroups of Patients with AL Amyloidosis with Distinct Clinical Characteristics	Shankara Anand Boston University
PA3 (#105)	Artificial intelligence for the detection of systemic amyloidosis	Delfina Cirelli Hospital Italiano de Buenos Aires
PA4 (#122)	Sex differences in the performance of the transthyretin amyloid cardiomyopathy (ATTR-CM) risk score	M Trejeeve Martyn Cleveland Clinic Foundation
PA5 (#147)	Timing and co-occurrence of red-flag diagnoses prior to a diagnosis of systemic light chain (AL) amyloidosis	Anita D'souza Medical College of Wisconsin
PA6 (#164)	Raising awareness to support early detection and diagnosis of Transthyretin (TTR) Amyloidosis in Ghana/West Africa from a public and health professionals trainers and trainees perspective	Kwaku Appiah-Kubi C K Tadam University of Technology and Applied Sciences
PA7 (#198)	Characterization of ATTR Amyloidosis by Phenotype from Claims Data in the United States and Japan: Preliminary Results from the OverTTuRe Study	Kevin Alexander Stanford University
PA8 (#271)	Improving Detection of AL Amyloidosis (IDEA)—testing AI cardiac algorithms in the real world	Angela Dispenzieri Mayo Clinic
PA9 (#366)	Prometeo: a simple and accurate amyloidosis subtyping by MS-based proteomics.	Pierluigi Mauri Consiglio Nazionale delle Ricerche
PA10 (#457)	Hereditary Transthyretin-related Amyloidosis ongoing clinical study: a baseline report of the first 3,167 participants	Pierre Engel Centogene GmbH

MONDAY, MAY 27, 2024 ORAL ABSTRACTS AND POSTERS

PA11 (#511)	Simplified Regression-based Echocardiogram Models for Earlier Identification of Cardiac Amyloidosis	Surendra Dasari Mayo Clinic
PA12 (#516)	The value of AI for enhancing suspicion of cardiac amyloidosis using electrocardiography and echocardiography: A narrative review	Martha Grogan Mayo Clinic h
PA13 (#544)	Evolving knowledge of “red flag” clinical features associated with TTR p.Val142Ile in a diverse electronic health record-linked biobank	Amy Kontorovich Mount Sinai Health System
PA14 (#545)	Machine Learning to Predict Mortality among Patients with Transthyretin Amyloid Cardiomyopathy	Ruizhi Liao Empallo Inc
PA15 (#551)	Measuring ATTRv-neuropathy in real world practice: a proposed protocol	Wilson Marques Junior Governor do Estado de Sao Paulo
PA16 (#561)	Exploring Patient- and Provider Characteristics Associated With The Utilization of Artificial-Intelligence-based Models to Detect Cardiac Amyloidosis (CA): A Subset Analysis From the On-going PREDICT-AMY Trial	Eli Muchtar Mayo Clinic

AL AMYLOIDOSIS BASIC SCIENCE

PA17 (#23)	Nanobodies as novel tools to target cardiac light chain amyloidosis	Luca Broggin Gruppo Ospedaliero San Donato
PA18 (#32)	The Cryo-EM structure of renal amyloid fibrils suggests structurally homogeneous multiorgan aggregation in AL amyloidosis.	Sarita Sarita Universita degli Studi di Milano
PA19 (#37)	Gene Expression Sets and Renal Profiling from the RAIN (Renal AL Amyloid Involvement and NEOD00) Trial	Cindy Varga Atrium Health
PA20 (#39)	Determinants of amyloidogenic behavior in AL amyloidosis patient-derived AL55 light chain: Insights from structural and biophysical studies	Sarita Sarita Universita degli Studi di Milano
PA21 (#40)	The Cryo-EM structure of renal amyloid fibrils suggests structurally homogeneous multiorgan aggregation in AL amyloidosis	Sarita Sarita Universita degli Studi di Milano
PA22 (#54)	Bone Marrow Interstitial Amyloid and Its Microenvironment	Ping Zhou Tufts University
PA23 (#59)	Intact IgG in Light Chain Amyloidosis	Olga Gursky Boston University
PA24 (#64)	Recombinant light chain production and analyses for the development of genetic diagnostic tests for AL	Huyen Phan Westmead Institute for Medical Research
PA25 (#70)	Role of the C-terminus disulfide bond in amyloid fibril formation of full-length human immunoglobulin λ 6a and λ 1 light chains	Lindsey Lampe Mayo Clinic
PA26 (#117)	Incidence of transthyretin amyloid cardiomyopathy from a French nationwide study of in- and out-patient databases	Thibaud Damy Republique Francaise

MONDAY, MAY 27, 2024 ORAL ABSTRACTS AND POSTERS

PA27 (#130)	Cell line xenografts to model serum free lambda light chain in vivo— a comparison of NOG vs humanized Interleukin 6 (IL-6) NOG mice	Ricardo Antonia Gate Bioscience
PA28 (#140)	Enhanced stabilisation of an amyloidogenic light chain using a tight binding variable heavy domain to mimic the homodimer complex	Alana Maerivoet University of Liverpool
PA29 (#168)	Deciphering the conformational landscape of amyloidogenic lambda light chains associated with AL amyloidosis	Sarita Sarita Universita degli Studi di Milano
PA30 (#170)	Amyloid free light chains disturb calcium transients and contractility in an AL cardiac amyloidosis 3D human spheroid model	Mélanie Bézard Republique Francaise
PA31 (#188)	Analyzing the contribution of neutrophils in amyloid clearance using murine amyloidoma models	Trevor Hancock University of Tennessee System
PA32 (#207)	Developing Conformation-Sensitive Antibodies Targeting Amyloid Aggregates of Lambda-6 Light Chains: A Structure-Based Approach for Therapeutic Intervention	Luis Del Pozo-Yauner University of South Alabama
PA33 (#210)	A SNAP23-mediated SNARE complex is necessary for Ig free light chain secretion in AL amyloidosis and Multiple Myeloma, representing a novel molecular target	Emre Karayol Harvard University
PA34 (#215)	Heterohybridomas Producing Human Light Chains: Success with CD138+ Cells from Myeloma and Polyclonal Gammopathy But Not AL Patients	Ping Zhou Tufts University
PA35 (#222)	AL-Base: An updated resource for analyzing amyloidogenic antibody light chain sequences	Gareth Morgan Boston University
PA36 (#254)	Characterization of a Novel Beta-sheet Peptide-Fc Fusion for Targeting Systemic Amyloid Deposits	Jonathan Wall University of Tennessee System
PA37 (#259)	Sequencing of amyloidogenic monoclonal immunoglobulin light chain repertoires from AL patients by combing RNA-based assay and mass spectrometry	Shuang Wang Peking University
PA38 (#269)	Non-coding RNAs regulate novel signaling pathways in AL amyloidosis that are targetable by FDA approved drugs	Oshrat Hershkovitz-Rokah Maccabi Healthcare Services
PA39 (#278)	Cardiotoxicity in light chain amyloidosis: Insights from a murine model with intramyocardial injection of patient-derived amyloidogenic light chains.	Efstathios Kastritis Ethniko kai Kapodistriako Panepistemio Athenon
PA40 (#294)	Temporal Changes in the Renal Cytokine Profile in Response to AA Amyloidosis Induce Macrophage Infiltration Enabling Host-Mediated Targeting of Therapeutic Chimeric Antigen Receptor Macrophages (CARM)	Manasi Balachandran The University of Tennessee System
PA41 (#338)	Truncation of the constant domain drives amyloid formation by immunoglobulin light chains: towards a physiological fibrillogenesis model	Francesca Lavatelli University of Pavia
PA42 (#391)	Kinetic evidence for multiple aggregation pathways in antibody light chain variable domains	Sherry Wong Boston University

MONDAY, MAY 27, 2024 ORAL ABSTRACTS AND POSTERS

PA43 (#404)	Cryo-electron microscopy structure of cardiac fibrils from an AL amyloidosis patient	Parker Bassett The University of Texas System
PA44 (#432)	Bone marrow plasma cells and immune microenvironment transcriptomic architecture in AL Amyloidosis during Daratumumab based therapy	Raphael Szalat Boston University
PA45 (#463)	N-glycosylation of clonal immunoglobulin light chains as a risk factor for AL amyloidosis: Benchmarking N-glycosylation prediction tools	Alice Nevone Regione Lombardia
PA46 (#517)	RNA-based Immunoglobulin repertoire sequencing is a useful tool for prediction and management of AL amyloidosis along with monoclonal gammopathies of clinical significance	Murielle ROUSSEL Universite de Limoges
PA47 (#522)	Characterization of cardiac AL amyloidosis in a transgenic mouse model	Christophe Sirac Universite de Limoges
PA48 (#525)	Single-Cell Mass Cytometry Analysis Reveals a Prominent Immune Suppressive Signature in AL Amyloidosis	Theophilus Tandoh City of Hope
PA49 (#560)	Hemostasis dysfunction induces senile APOA2 amyloidosis in a mouse model	Christophe Sirac Universite de Limoges

DIAGNOSIS OF AL AMYLOIDOSIS

PA50 (#31)	Diagnosing Cardiac Amyloid: Can we ditch the bioprome yet?	Vinayak Hegde Cleveland Clinic
PA51 (#46)	Screening for Systemic Light-chain Amyloidosis in Patients Over 60 years of Age with λ Monoclonal Gammopathies	Ping Zhou Tufts University
PA52 (#49)	V122I TTR and AL κ -type in a Patient with Cardiac Involvement and Spinal Stenosis	Xia Wu Tufts University
PA53 (#61)	Positive cardiac scintigraphy with Tc-99m DPD-SPECT: Diagnosis is not always ATTR cardiac amyloidosis	Ioannis Panagiotopoulos Onaseio Kardiocheirurgiko Kentro
PA54 (#65)	Prevalence, Incidence, And Characterization Of Light Chain Amyloidosis In The Usa: A Real-World Analysis Utilizing Electronic Health Records (EHR)	Pedro Laires AstraZeneca PLC
PA55 (#87)	Increasing Prevalence and Incidence of AL Amyloidosis Among Older Adults in the US	Preeti S. Bajaj, Phd Prothena Biosciences Inc.
PA56 (#119)	Transverse Carpal Ligament Analysis as Screening Tool for Amyloidosis	Seunghyuk Daniel Yang Trinity Health
PA57 (#124)	Predictors factors of mortality in advanced cardiac AL Amyloidosis:A prospective Cohort study - for improving cardiac stratification	Amira Zaroui Universite Paris-Est Creteil Val de Marne
PA58 (#177)	A Subset Of Patients With Renal AL-Amyloidosis Present Without Significant Proteinuria And Display Poor Renal Outcomes	Camille Cohen Republique Francaise
PA59 (#179)	The incidence of AL amyloidosis in patients with carpal tunnel syndrome	Gaja Cvejić Vidali Univerza v Ljubljani

MONDAY, MAY 27, 2024 ORAL ABSTRACTS AND POSTERS

PA60 (#206)	Small Fiber Neuropathy in AL Amyloidosis: Clinical and Prognostic Implications	Efstathios Kastritis Ethniko kai Kapodistriako Panepistemio Athenon
PA61 (#249)	There is more than meets the eye: an unexpected case of cardiac Amyloidosis.	Andrea Nevi Universita degli Studi di Verona
PA62 (#255)	Renal AL amyloidosis : an unusual presentation	Tarek Ashour Cleveland Clinic
PA63 (#308)	Role of Amyloidosis screening in a Monoclonal Gammopathy of Undetermined Significance (MGUS) clinic: Results from a pilot study at the University of Calgary	Victor Jimenez Zepeda Alberta Government
PA64 (#309)	Referral patterns in AL and ATTR Amyloidosis: Initial experience from the Amyloidosis Program of Calgary: Role of a Multidisciplinary approach	Victor Jimenez Zepeda Alberta Government
PA65 (#311)	Clinical significance of the Monoclonal Gammopathy of Undetermined Significance (MGUS) -like phenotype in patients with AL amyloidosis treated with Bortezomib-Containing Regimens (BCR) at the Amyloidosis Program of Calgary (APC)	Victor Jimenez Zepeda Alberta Government
PA66 (#326)	Patient-reported Diagnostic Journey of Patients Recently Diagnosed with Light Chain Amyloidosis: Data from the Amyloidosis Research Consortium's 2022 and 2023 Amyloidosis Community Surveys	Sabrina Rebello Amyloidosis Research Consortium
PA67 (#347)	Tracheobronchial Amyloidosis is Composed of Polytypic Immunoglobulins: A Report of 603 Cases	Daniel Larson Mayo Clinic
PA68 (#360)	Amyloid typing by liquid chromatography-tandem mass spectrometry analysis of unfractionated unfixed abdominal fat aspirates	Giulia Mazzini Regione Lombardia
PA69 (#363)	Latvian National Amyloidosis Registry Data 2020-2023	Valdis Ģībietis Rigas Stradina Universitate
PA70 (#368)	To Treat or Not to Treat – a Rare Case of Cardiogenic Shock and Isolated Cardiac Amyloidosis	Annie Mcgregor Rush University
PA71 (#380)	Setting up proteomic typing from scratch in Greece: challenges and opportunities	Julie Courraud Ethniko kai Kapodistriako Panepistemio Athenon
PA72 (#382)	Fat aspiration for minimally-invasive amyloidosis screening from an external amyloidosis clinic	Christoph Kimmich Stadt Oldenburg
PA73 (#407)	An Unusual Journey: From Systemic to Localized AL Amyloidosis	Roberta Shcolnik Szor Hospital 9 de Julho
PA74 (#410)	Challenges in Amyloidosis Typing: The Role of Mass Spectrometry in a Middle-Income Country	Roberta Shcolnik Szor Hospital 9 de Julho
PA75 (#417)	Exploring the utility of M-quant in the assessment of AL (immunoglobulin light chain) amyloidosis	Angela Dispenzieri Mayo Clinic
PA76 (#419)	Subacute Axonal Polyradiculoneuropathy Presentation in AL and TTRv Amyloidosis	David Polston Cleveland Clinic

MONDAY, MAY 27, 2024 ORAL ABSTRACTS AND POSTERS

PA77 (#438)	A case of Local AL Amyloidosis with repeated recurrences	Kai Miyazaki Nihon Ika Daigaku
PA78 (#448)	Subcutaneous daratumumab interferes with amyloid typing by liquid chromatography-tandem mass-spectrometry on subcutaneous fat.	Serena Caminito Universita degli Studi di Pavia
PA79 (#458)	An ultra-sensitive laser microdissection-mass spectrometry-based method for the identification of subtype specific amyloidogenic proteins from fat aspirates	Hans Christian Beck Region Syddanmark
PA80 (#459)	Systemic x localized AL amyloidosis: Investigation of an atypical case	Diane Xavier De Ávila Fluminense Federal University
PA81 (#484)	Is AL Amyloidosis A Diagnostic Puzzle Or Rare Entity : A single centre experience	Bhavani Mandava Siksha O Anusandhan
PA82 (#486)	Pulmonary and nodal light chain amyloidosis as a presenting feature of Waldenstrom's Macroglobulinemia: A case report	Aaron Lobo Yale New Haven Health System
PA83 (#503)	De Novo AL Amyloidosis In Renal Allograft-Case Report And Literature Review	Batuhan Bulan Istanbul Universitesi-Cerrahpasa
PA84 (#520)	Cardiac Amyloidosis and Cardiac Sarcoidosis in a Patient with Heart Failure	Jennifer Maning Northwestern Memorial HealthCare
PA85 (#534)	Recurrent pleural effusion and AL amyloidosis diagnosis	Diane Xavier De Ávila Fluminense Federal University

PATHOLOGY

PA86 (#55)	Clinical and genetic profiles of patients with hereditary and wild-type transthyretin amyloidosis: the Transthyretin Cardiac Amyloidosis Registry in the state of São Paulo, Brazil (REACT-SP)	Fabio Fernandes Governor do Estado de Sao Paulo
PA87 (#57)	Pathological features in patients with hereditary transthyretin amyloidosis long after liver transplantation.	Tomoaki Taguchi Kumamoto Daigaku
PA88 (#58)	Global patterns of tissue typing in amyloidosis: Results of a survey by the International Society of Amyloidosis (ISA)	Hironobu Naiki Fukui Daigaku
PA89 (#67)	Double Trouble: A case of biopsy proven ATTR and AL cardiac amyloid	Arianne Clare Agdamag Cleveland Clinic
PA90 (#79)	Unraveling the protection of neuronal cytoskeleton and synaptic structures by TTR	Isabel Cardoso Universidade do Porto
PA91 (#88)	Gallbladder Amyloid is Often Unexpected and May Have Systemic Implications	Catherine Hagen Mayo Clinic
PA92 (#91)	Diagnostic support for amyloidosis at the Amyloidosis Center Kumamoto University	Mitsuharu Ueda Kumamoto Daigaku
PA93 (#149)	Advancing Amyloidosis Management in Belgium; The Belgian Amyloidosis Consortium (Be.Amycon)	Annelore Vandendriessche Universiteit Gent
PA94 (#154)	Dual Amyloidosis: A Clinicopathologic and Proteomic Analysis of 65 Patients	Joanna Dalland Mayo Clinic

MONDAY, MAY 27, 2024 ORAL ABSTRACTS AND POSTERS

PA95 (#157)	Advancing Amyloidosis Management in Belgium: The Belgian Amyloidosis Consortium (Be.Amycon)	Annelore Vandendriessche Universiteit Gent
PA96 (#205)	Amyloid Infiltration of the Skeletal Muscle Infiltration is Common With Cardiac Amyloidosis	Sarah Cuddy Harvard University
PA97 (#342)	Subtype frequency of systemic amyloidosis listed in the Annual of the Pathological Autopsy Cases in Japan	Aina Yamaguchi Fukui Daigaku
PA98 (#372)	The Detection Yield of Surrogate Tissue Biopsies across Classes of Systemic Amyloidosis: Review of 4,027 Cases	Natasha Burke Boston Medical Center
PA99 (#377)	Salivary Gland Amyloidosis: Proteomic Identification and Clinicopathologic Characterization of 57 cases.	April Chiu Mayo Clinic
PA100 (#413)	Quantitation of daratumumab among AL amyloidosis patients by M-quant measurement	Angela Dispenzieri Mayo Clinic
PA101 (#422)	Gastrointestinal Amyloid Screening Study (GASS): Is Screening for Amyloid in the Gastrointestinal Tract Useful?	Rola Khedraki Scripps Health
PA102 (#469)	Healthcare Amyloidosis European Registry (HEAR REGISTRY): Study design and methods	Mounira Kharoubi Universite Paris-Est Creteil Val de Marne
PA103 (#479)	Comparison of two free light chain assays: performance of the free light chain ratio as risk factor for MGUS progression	Qian Wang Mayo Clinic
PA104 (#513)	A UK experience of 874 endomyocardial biopsies for the diagnosis of amyloidosis	Joshua Bomszyk University of London
PA105 (#546)	The role of gastrointestinal involvement as a predictor of caregiver burden severity in cardiac amyloidosis	Shoujit Banerjee State of California

PROGNOSIS AL AMYLOIDOSIS

PA106 (#35)	Prognostic impact of cytogenetic abnormalities by FISH in systemic AL amyloidosis in the era of daratumumab and bortezomib-based frontline combination regimens	Rajshekhkar Chakraborty Columbia University
PA107 (#76)	Time to next treatment is longer in patients with a haematological complete response who are FLC-MS negative vs. positive	Joshua Bomszyk University of London
PA108 (#95)	Incidence of Second Primary Malignancies in Patients with AL amyloidosis and The Impact of Disease Stage and Therapies	Efstathios Kastritis Ethniko kai Kapodistriako Panepistemio Athenon
PA109 (#96)	Insights into Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The 12-year Experience of Cleveland Clinic	Utkarsh Goel Cleveland Clinic
PA110 (#108)	Epidemiological perspectives of amyloidosis in Argentina: results of an analysis of incidence and mortality in a population affiliated to a Medical Care Program	Delfina Cirelli Hospital Italiano de Buenos Aires
PA111 (#131)	Clinical Features of AL Amyloidosis Patients Harboring Clonal Hematopoiesis of Indeterminate Potential	Paolo Lopodote Steward Health Care

MONDAY, MAY 27, 2024 ORAL ABSTRACTS AND POSTERS

PA112 (#143)	Thrombotic and Bleeding complications in patients with AL Amyloidosis	Efstathios Kastritis Ethniko kai Kapodistriako Panepistemio Athenon
PA113 (#156)	Evaluation of Minimal Residual Disease using Next Generation Flow Cytometry in patients with AL amyloidosis	Efstathios Kastritis Ethniko kai Kapodistriako Panepistemio Athenon
PA114 (#160)	Is the Cardiac Amyloidosis Artificial Intelligence Electrocardiography (CA-AI-ECG) model useful in predicting outcomes in Multiple Myeloma (MM) patients without known Amyloidosis undergoing Autologous Stem Cell Transplant (ASCT)?	Angela Dispenzieri Mayo Clinic
PA115 (#186)	Identifying Early Suboptimal Hematological Response in Patients with AL Amyloidosis Treated with Bortezomib-based Therapy.	Nirija Ranjit Anderson Queensland Government
PA117 (#268)	Re-evaluation of Mayo 2004 and Revised Mayo 2012 staging in patients with AL amyloidosis in the era of new therapies	Efstathios Kastritis Ethniko kai Kapodistriako Panepistemio Athenon
PA118 (#280)	Validating the performance of renal staging in AL amyloidosis patients undergoing autologous stem cell transplantation	Eli Muchtar Mayo Clinic
PA119 (#299)	Clinical profile and treatment outcomes in primary (AL) amyloidosis from low- and middle-income country (LMIC)	Pankaj Malhotra Government of India
PA120 (#332)	Mortality patterns among patients with cardiac amyloidosis in a tertiary care center in Latin America	Javier Torres Estado Peruano
PA121 (#348)	Predictive value of free light chain burden in patients newly diagnosed with AL amyloidosis treated with CyBorD or DaraCyBorD	Brendan Saunders Harvard University
PA122 (#354)	Inclusion criteria of clinical trials select patients with AL amyloidosis with favorable outcome and exclude almost one half of the real-life population.	Claudia Bellofiore Universita degli Studi di Pavia
PA123 (#355)	Long-term evaluation of amyloidosis diseases in Germany: National Clinical Amyloidosis Registry	Ute Hegenbart Universitat Heidelberg
PA124 (#361)	Predictors of timely and deep renal responses in AL amyloidosis	Matthew Rees Mayo Clinic
PA125 (#367)	Predictors of timely and deep cardiac responses in AL amyloidosis	Matthew Rees Mayo Clinic
PA126 (#384)	Refining prognostication in systemic AL amyloidosis	Jahanzaib Khwaja HM Government of the UK of Great Britain and Northern Ireland
PA127 (#392)	Long-term hematologic remission in Immunoglobulin Light Chain (AL) Amyloidosis	Efstathios Kastritis Ethniko kai Kapodistriako Panepistemio Athenon
PA128 (#454)	Sustained paradoxical vasodilation and blood pressure lowering in response to sympathetic stimulation as	Efstathios Kastritis Ethniko kai Kapodistriako Panepistemio Athenon

MONDAY, MAY 27, 2024 ORAL ABSTRACTS AND POSTERS

markers of disease severity and poor survival in primary AL amyloidosis.

PA129 (#456)	A predictive model for day-100 transplant-related mortality in AL amyloidosis	Eli Muchtar Mayo Clinic
PA130 (#467)	IgM Immunoglobulin light chain amyloidosis: the quest for prognostic biomarkers in a rare disease with two distinct clonal phenotypes	Marco Basset Regione Lombardia
PA131 (#468)	Outcomes of patients with newly diagnosed light chain amyloidosis according to eligibility for clinical trials: Experience of a single institution	Jose Miguel Mateos Perez Hospital Clinic de Barcelona
PA132 (#490)	A European REgistry and sample sharing networK to promote the diagnosis and management of light chain Amyloidosis: The EUREKA study	Mario Nuvolone Universita degli Studi di Pavia
PA133 (#491)	Real-life experience on light chain cardiac amyloidosis: delay diagnosis is still a major issue	Morgane Thiry Universite catholique de Louvain
PA134 (#494)	Clinical implications of genetic interphase fluorescence in situ hybridization aberrations in systemic light chain amyloidosis	Sara Oubari Universitat Duisburg-Essen
PA135 (#543)	Functional Capacity in Light Chain Amyloid Cardiomyopathy: Prognostic Value and Changes With Therapy	Olivier Clerc Mass General Brigham Inc
PA136 (#550)	Prognostic significance of circulating tumor cells assessed with next generation flow cytometry in patients with AL amyloidosis	Efstathios Kastritis Ethniko kai Kapodistriako Panepistemio Athenon

TREATMENT AL

PA137 (#50)	Real-World Outcomes and Treatment Patterns in AL-Amyloidosis (AL-A) in Austria: An Analysis from the Austrian Interdisciplinary Amyloidosis Registry (AIDA)	Wolfgang Willenbacher
PA138 (#60)	Daratumumab is one of the main drivers of outcome improvement in AL amyloidosis	Elena Alejo Junta de Castilla y Leon
PA139 (#66)	Treatment outcome of DCyBorD therapy on patients with advanced systemic AL amyloidosis	Nagaaki Katoh Shinshu Daigaku
PA140 (#90)	The role of deferred autologous stem cell transplantation in patients with AL amyloidosis who had VGPR or CR after bortezomib-based induction therapy	Joon Young Hur Hanyang Educational Corporation
PA141 (#97)	Outcomes of Venetoclax based Therapy in Patients with t(11;14) Light Chain Amyloidosis After Failure of Daratumumab based Therapy	Utkarsh Goel Cleveland Clinic
PA142 (#103)	Feasibility of a Novel Academic Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis	Eyal Lebel Hebrew University of Jerusalem
PA143 (#107)	Renal response to treatment in patients with Immunoglobulin Light Chain Amyloidosis	Delfina Cirelli Hospital Italiano de Buenos Aires

MONDAY, MAY 27, 2024 ORAL ABSTRACTS AND POSTERS

PA144 (#113)	Outcomes in Patients with AL Amyloidosis with Renal Involvement: Findings from the TriNetX Database	Richa Manwani AstraZeneca PLC
PA145 (#114)	A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed by Autologous Stem Cell Transplant or DARA-VCD Consolidation and Daratumumab Maintenance in patients with Newly Diagnosed AL Amyloidosis	Patrick Hagen Trinity Health
PA146 (#142)	A Retrospective Analysis of Primary AL-Amyloidosis in a Tertiary Care Cancer Center in India	Anupam Brahma Tata Medical Centre Trust
PA147 (#162)	Bortezomib, pomalidomide, and dexamethasone is a potential effective regimen for patients with relapse and refractory AL amyloidosis and monoclonal immunoglobulin deposition disease	Yang Liu Peking University
PA148 (#163)	Safety and Efficacy of SGLT2 Inhibitors for Amyloid Light-Chain Cardiomyopathy: An Early Experience	Frederick M. Lang Columbia University
PA149 (#178)	Phase 1b study evaluating the safety and efficacy of ABBV-383 monotherapy in patients with light chain amyloidosis	Vaishali Sanchorawala Boston Medical Center
PA150 (#183)	Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study by the European Myeloma Network	Efstathios Kastiris Ethniko kai Kapodistriako Panepistemio Athenon
PA151 (#184)	Treatment Patterns for AL Amyloidosis after Frontline Daratumumab, Bortezomib, Cyclophosphamide and Dexamethasone Treatment Failures	Saurabh Zanwar Mayo Clinic
PA152 (#187)	From TTR to AL: Novel Conformation-Specific Antibodies to Combat Systemic Amyloidosis	Yulong Sun Paradox Immunotherapeutics Inc.
PA153 (#195)	Early hematological response and safety of isatuximab, pomalidomide and dexamethasone (IsaPd) in relapsed AL amyloidosis: interim results of the IsaMYP phase II study.	Murielle ROUSSEL Universite de Limoges
PA154 (#212)	Defying The Odds: A 30-Year Journey Through AL Amyloidosis Research With A Focus On Recent Structural/Clinical Barriers To Clinical Trial Enrollment	Vaishali Sanchorawala Boston Medical Center
PA155 (#238)	Outcomes of Daratumumab Bortezomib Thalidomide Dexamethasone in treatment-naïve systemic AL amyloidosis	Jahanzaib Khwaja HM Government of the UK of Great Britain and Northern Ireland
PA156 (#242)	Demographic and Baseline Characteristics of Participants in Cardiac Amyloid Reaching for Extended Survival (CARES) Trials: Two Randomized, Double-blind, Placebo-controlled, International Phase 3 Trials Assessing the Safety and Efficacy of Anselamimab (CAEL-101) in Patients with European Modification of Mayo 2004 Stage IIIa or Stage IIIb AL Amyloidosis	Guoqing Sheng AstraZeneca PLC

MONDAY, MAY 27, 2024 ORAL ABSTRACTS AND POSTERS

PA157 (#266)	Insights into Systemic AL Amyloidosis Care in India: A Retrospective Analysis from the Amrita Amyloid Centre	Aparna Hari Mata Amritanandamayi Math
PA158 (#301)	Comparison of three bortezomib-containing regimens for the treatment of newly diagnosed AL amyloidosis	Victor Jimenez Zepeda Alberta Government
PA159 (#306)	Clinical outcomes for patients with Stage III AL amyloidosis: Experience from the Amyloidosis Program of Calgary	Victor Jimenez Zepeda Alberta Government
PA160 (#328)	Trial in Progress: A Phase 1/1a Study of Venetoclax, Ixazomib and Dexamethasone for Relapsed/Refractory Light Chain Amyloidosis	Michael Rosenzweig City of Hope
PA161 (#345)	3 years follow-up of Venetoclax in Relapsed or Refractory AL Amyloidosis with t(11;14) and BCL2 expression	Rahel Schwotzer Universitat Zurich
PA162 (#359)	Daratumumab in First-Line Combination Treatment of AL Amyloidosis: Experience from Riga, Latvia	Valdis Ģībietis Rigas Stradina Universitate
PA163 (#397)	Stem cell collection in AL patients after different induction and mobilization therapies	Joseph Kauer Universitat Heidelberg
PA164 (#437)	The Safety and Efficacy of Ciltacabtagene Autoleucel in Refractory Mayo stage IIIA AL Amyloidosis: A Case Report.	Heather Landau Memorial Sloan Kettering Cancer Center
PA165 (#483)	DRD vs D-VCD in patients with newly diagnosed AL amyloidosis	Sorina Nicoleta Badelita Institutul Clinic Fundeni
PA166 (#485)	Long term outcome of a sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis	Marco Basset Regione Lombardia
PA167 (#497)	Arthropathy of the knees as initial manifestation of AL amyloidosis	Morgane Thiry Universite catholique de Louvain
PA168 (#547)	Beyond MRD: Dead Reckoning Toward the Cure	Nate Wetter University of Illinois System
PA169 (#554)	A Heartfelt Response: A Case of Cardiac Amyloidosis and Multiple Myeloma Treated with Chimeric Antigen Receptor T-cell Therapy	George Tsourdinis The University of Chicago

TUESDAY, MAY 28, 2024 ORAL ABSTRACTS AND POSTERS**IMAGING**

OB1 (#296)	Changes in Organ-Specific Amyloid Load Assessed by Serial PET/CT Imaging of Iodine (124I) Evuzamitide – Correlation with Serum Biomarkers	Emily Martin University of Tennessee System
OB2 (#444)	Diagnostic performance of [18F]-Florbetaben PET for the detection of cardiac involvement in AL amyloidosis: first results of the MoRbiDA trial	Paolo Milani Universita degli Studi di Pavia
OB3 (#287)	First-in-Human Cardiac and Whole-Body 124I-evuzamitide (AT-01) PET/MRI in Systemic Amyloidosis	Morris Kim Oregon Health & Science University
OB4 (#401)	Comparative Analysis of Clinical and Echocardiographic Variations in Cardiac Amyloidosis Subtypes	Faysal Massad Mayo Clinic
OB5 (#405)	The limitations of 99mTc-dpd scintigraphy in tracking treatment response in transthyretin amyloid cardiomyopathy (ATTR-CM)	Julian Gillmore University of London
OB6 (#383)	Utility of 18F-PET Scintigraphy to detect inflammatory light chain proteotoxicity in cardiac AL amyloidosis	Jahanzaib Khwaja HM Government of the UK of Great Britain and Northern Ireland
OB7 (#532)	Prevalence of amyloid deposition in patients undergoing surgical myectomy for presumed hypertrophic cardiomyopathy	David Katzianer Cleveland Clinic
OB8 (#18)	Prevalence of transthyretin amyloid cardiomyopathy in patients with hypertrophic cardiomyopathy: Final analysis of the TTRACK study	Thibaud Damy

AMYLOID LOOK ALIKES

OB9 (#327)	Epidemiology and clinical characteristics of patients with monoclonal gammopathy of renal significance (MGRS) in a diverse population	Evgenia Granina Boston Medical Center
OB10 (#313)	Light-Chain MGUS defined as per the Revised definition of the ISTOPMM Study: Experience from the University of Calgary MGUS Clinic	Victor Jimenez Zepeda Alberta Government

ATTR AMYLOIDOSIS, BASIC SCIENCE

OB11 (#324)	Deciphering the pathogenesis of transthyretin cardiac amyloidosis in a humanized mouse model	Xiaokang Wu
OB12 (#104)	Rac1 activation triggers axonal cytoskeleton dysfunction in Transthyretin Amyloid Polyneuropathy	Marcia Liz Universidade do Porto
OB13 (#449)	NMR reveals structural and dynamics changes of transthyretin that were hidden in X-ray studies	Alessandra Corazza Universita degli Studi di Udine, Italy
OB14 (#451)	NMR study of Transthyretin Binding by Monovalent and Bivalent Stabilizers in Human Serum	Alessandra Corazza Universita degli Studi di Udine
OB15 (#270)	Whole tissue proteomic analyses of cardiac ATTR and AL unveil mechanisms of tissue damage.	Taxiarchis Kourelis Mayo Clinic

TUESDAY, MAY 28, 2024 ORAL ABSTRACTS AND POSTERS

OB16 (#339)	What the structures of amyloids teach us about amyloid pathology	Rodrigo Gallardo Katholieke Universiteit Leuven
PB1 (#226)	ALXN2220: high-resolution live-cell imaging of antibody-mediated cardiac ATTR amyloid depletion	Peter Christian Kahr Neurimmune
PB2 (#56)	A structural approach to understanding transthyretin amyloidosis	Shumaila Afrin The University of Texas System
PB3 (#63)	Detection of circulating transthyretin amyloid aggregates in plasma: a novel biomarker for transthyretin amyloidosis	Rose Pedretti The University of Texas System
PB4 (#78)	Survival of patients with transthyretin amyloid cardiomyopathy (ATTR-CM) according to the dispensed daily dose of loop diuretics, based on SNDS French claims database	Vincent Algalarrondo Bichat Hospital
PB5 (#81)	Testing optimized Tolcapone derivatives for plasma TTR stabilization aiming improved therapies in TTR amyloidosis	Maria Rosario Almeida Universidade do Porto
PB6 (#134)	Structural homogeneity of ex-vivo ATTR-T60A fibrils revealed by Cryo-EM	Maria Del Carmen Fernandez-Ramirez The University of Texas System
PB7 (#150)	Structural Variations in ATTR Amyloidosis: Cryo-Electron Microscopy Examination of V122I and V122Δ Mutations	Yasmin Ahmed The University of Texas System
PB8 (#172)	Care pathways of transthyretin amyloid cardiomyopathy from a French nationwide study of in- and out-patient databases	Thibaud Damy Republique Francaise
PB9 (#213)	Cryo-EM study of fibril polymorphism in ATTR amyloidosis	Binh Nguyen The University of Texas System
PB10 (#293)	Engineering hiPSC-Derived Tissue Models for Advanced Amyloidosis Research and Therapy Development	Maria Del Pilar Montero Calle CIMA Universidad de Navarra
PB11 (#322)	Hsp40/70/110 chaperones limit human Transthyretin protein aggregation	Anita Manogaran Society of Jesus
PB12 (#337)	Naturally occurring antibodies as biomarker for cardiac ATTR amyloidosis	Stephan Settelmeier Universitat Duisburg-Essen
PB113 (#352)	Biochemical characterization of transthyretin aggregates in blood of ATTR amyloidosis patients	Lanie Wang The University of Texas System
PB14 (#370)	In vitro formation of amyloid fibrils from full-length transthyretin templated by ATTRv seeds	Luis O. Cabrera Hernández The University of Texas System
PB15 (#376)	Circulating transcriptome profiling in cardiac TTR amyloidosis by genome-wide analysis.	Inmaculada Moreno Gázquez
PB16 (#455)	Elucidation of the Mechanism of Amyloid A and Transthyretin Formation Using Mass Spectrometry-Based Absolute Quantification	Yukako Shintani-Domoto Nihon Ika Daigaku
PB17 (#481)	Degradation versus fibrillogenesis, two alternative pathways modulated by seeds and glycosaminoglycans	Guglielmo Verona University of London
PB18 (#524)	Transthyretin amyloidosis in the second decade of life: a rare genetic variant	Plínio José Wolf Governo do Estado de Sao Paulo

TUESDAY, MAY 28, 2024 ORAL ABSTRACTS AND POSTERS

PB19 (#563) Ventricular arrhythmia in transthyretin cardiac amyloidosis in a Brazilian population: outcomes of transthyretin cardiac amyloidosis registry in the state of São Paulo (REACT-SP) Georgina Del Cisne Jadán Luzuriaga

PB20 (#567) Analysis of the right ventricle between the different subtypes of ATTR amyloidosis with cardiac involvement in a cohort of patients Natalia Pereira Incor

DIAGNOSIS OF ATTRV

PB21 (#16) A final, consolidated overview of 16 years of data from the Transthyretin Amyloidosis Outcomes Survey Angela Dispenzieri Mayo Clinic

PB22 (#74) ATTR Cardiomyopathy in Early and Late onset ATTRV30M: Two Sides of the Same Coin? Vincent Algalarrondo Bichat Hospital

PB23 (#75) Hereditary transthyretin amyloidosis with cardiomyopathy: which are the TTR variants associated with early-onset involvement? Vincent Algalarrondo Bichat Hospital

PB24 (#127) Motor unit remodelling as an early biomarker of disease involvement in hereditary transthyretin amyloidosis Antonia Carroll The University of Sydney

PB25 (#128) Serum Neurofilament light chain in hereditary transthyretin amyloidosis: Validation in real-life practice Antonia Carroll The University of Sydney

PB26 (#129) The spectrum of neuropathy in hereditary transthyretin amyloidosis (ATTRv) in Australia Antonia Carroll The University of Sydney

PB27 (#138) Neurofilament light chain as a biomarker for hereditary ATTR amyloidosis - Correlation between neurofilament light chain and nerve conduction study - Masateru Tajiri Shinshu Daigaku

PB28 (#221) Unveiling the Hidden Threat: A Case of Concurrent Mitral Regurgitation and Cardiac Amyloidosis Dipan Uppal Cleveland Clinic

PB29 (#224) Ocular Involvement in Transthyretin Amyloidosis patients - Bahia State of Brazil Claudia Galvao-Pedreira Fundacao Bahiana para Desenvolvimento das Ciencias

PB30 (#225) Comparison of the Simoa and MSD R-PLEX assay to assess serum neurofilament light chain levels in hereditary transthyretin amyloidosis Milou Berends Rijksuniversiteit Groningen

PB31 (#250) Comparison between wild type and Val142Ile ATTR cardiomyopathy clinical presentation in the Brazilian population: Results of the Transthyretin Cardiac Amyloidosis Registry in the state of São Paulo, Brazil (REACT/SP) Marcus Simoes Governo do Estado de Sao Paulo

PB32 (#262) Hereditary Transthyretin (ATTRv) Amyloidosis in the Middle East. The Abdali National Amyloidosis Center's Experience Ramzi Tabbalat Abdali Hospital

PB33 (#272) High-sensitivity cardiac troponin T to exclude cardiac involvement in TTR variant carriers and ATTRv amyloidosis patients Hendrea Tingem Rijksuniversiteit Groningen

TUESDAY, MAY 28, 2024 ORAL ABSTRACTS AND POSTERS

PB34 (#277)	Navigating the Diagnostic Odyssey: Unveiling Cardiac Amyloidosis through Gastrointestinal Biopsy	Eson Ekpo Scripps Health
PB35 (#289)	CENTINNELA program: access to use of Neurofilament Light Chain for diagnosis at follow-up of patients and carriers with ATTRv	Álvaro Gragera Juan Ramon Jimenez University Hospital
PB36 (#335)	Transthyretin amyloid polyneuropathy in France: a cross-sectional study with 413 patients and real-world tafamidis meglumine use (2009-2019)	David Adams Republique Francaise
PB37 (#340)	V122I Hereditary Transthyretin Amyloidosis in Brazil: an Endemic Variant	Anna Paula Covaleski Universidade Federal de Pernambuco
PB38 (#379)	Clinical impact of Genetic Testing Screening in families with Hereditary Transthyretin Amyloidosis	Nerea Mora Ayestarán Universidad Autonoma de Madrid
PB39 (#385)	ECG changes in asymptomatic ATTRv carriers developing ATTR cardiomyopathy.	Belen Peiro-Aventin Universidad Autonoma de Madrid
PB40 (#406)	Non-ATTR clinical manifestations in attr patients and carriers	Sasha Zivkovic Yale University
PB41 (#439)	ATTRv distribution in a continental multiracial country	Wilson Marques Junior Governo do Estado de Sao Paulo
PB42 (#473)	Diagnostic yield of early gene panel testing in patients with suspected cardiac amyloidosis	Milou Berends Rijksuniversiteit Groningen
PB43 (#476)	Sustained Ventricular Tachycardia as an isolated feature of transthyretin amyloidotic cardiomyopathy - Val50Met	Larissa Bruscky Governo do Estado de Sao Paulo
PB44 (#480)	Oxidative conversion of transthyretin during storage of formalin-fixed clinical amyloid samples results in the formation of the His90Asp variant.	Diana Canetti University of London
PB45 (#492)	Clinical phenotype of Romanian patients with transthyretin-type hereditary amyloidosis due to Val 107 mutation	Sorina Nicoleta Badelita Institutul Clinic Fundeni
PB46 (#499)	A tale of two proteins	Suresh Yerra Mayo Clinic
PB47 (#541)	Left Ventricular Assist Device Therapy in ATTR Cardiac Amyloid	Jennifer Marsidi Rush University

DIAGNOSIS OF ATTR_{wT}

PB48 (#3)	International prevalence of transthyretin amyloid cardiomyopathy in high-risk patients with heart failure and preserved or mildly reduced ejection fraction	Sergi Yun Bellvitge University Hospital,
PB49 (#20)	Differences in cardiac nuclear imaging results with 99mTc-DPD, 99mTc-PYP, and 99mTc-HMDP bone radiotracers in patients with left ventricular hypertrophy of unknown	Javier De Haro Comunidad de Madrid

TUESDAY, MAY 28, 2024 ORAL ABSTRACTS AND POSTERS

etiology screened for transthyretin amyloid cardiomyopathy in the TTRACK study

PB50 (#21)	Clinical red flags associated with transthyretin amyloid cardiomyopathy in patients with unexplained hypertrophic cardiomyopathy: results of the TTRACK study	Thibaud Damy Republique Francaise
PB51 (#26)	Cardiac amyloidosis in elderly with positive scintigraphy and monoclonality: a diagnostic dilemma	Maria Alfarano Regione Lazio
PB52 (#30)	Development of a Risk Score for Positive Tenosynovial Biopsy for Amyloidosis at Carpal Tunnel Release	Dafang Zhang Harvard University
PB53 (#33)	Cardiac Amyloidosis ,From Early Suspicion to Early Detection	Dr. Fayez Al Zubair Kingdom of Saudi Arabia
PB54 (#68)	Prevalence and incidence of ATTR amyloidosis in the united states: insights from claims database and electronic health records	Pedro Laires AstraZeneca PLC
PB55 (#85)	Evaluating the current physicians' knowledge and patients' pathways for diagnosing transthyretin cardiac amyloidosis (ATTR-CM) in France: An extensive survey of diverse medical specialists.	Silvia Oghina Universite Paris-Est Creteil Val de Marne
PB56 (#92)	Lip salivary gland biopsy after positive endomyocardial biopsy shows poor correlation	Ryan Davey London Health Sciences Foundation
PB57 (#109)	Current practices and access to cardiac bone scans for the detection of transthyretin cardiac amyloidosis based on the results of a large national electronic survey	Fabien Hyafil Republique Francaise
PB58 (#110)	Amyloid typing by mass spectrometry is necessary to properly diagnosis transthyretin amyloidosis (ATTR) in patients with a history of MGUS or smoldering myeloma.	Jessica Chapman Memorial Sloan Kettering Cancer Center
PB59 (#112)	Subtype distribution of amyloidosis in the united states: insights from an electronic health records database analysis	Pedro Laires AstraZeneca PLC
PB60 (#125)	Prevalence of Wild-Type Transthyretin Cardiac Amyloidosis in Elderly Subjects from the General Population	Alberto Aimo Fondazione Toscana Gabriele Monasterio per la Ricerca Medica e di Sanita Pubblica
PB61 (#126)	Wild-type transthyretin cardiac amyloidosis: sex differences in prevalence, cardiac and extracardiac phenotypes, and prognosis	Amira Zaroui Universite Paris-Est Creteil Val de Marne
PB62 (#146)	Investigating Relationship of LVSD Size and Patient Characteristics of those Diagnosed with TTR Cardiac Amyloid	Spencer Martin London Health Sciences Foundation
PB63 (#148)	Transthyretin amyloid cardiomyopathy in France: A medical chart multi-center study (333 patients)	Thibaud Damy Republique Francaise

TUESDAY, MAY 28, 2024 ORAL ABSTRACTS AND POSTERS

PB64 (#158)	Multidisciplinary approach for the early detection of amyloid in patients who undergo carpal tunnel syndrome or lumbar stenosis surgery.	Núria Orta Tomàs Govern de les Illes Balears
PB65 (#161)	Transthyretin Cardiac Amyloid: Broad phenotypic spectrum and implications for diagnosis	Dipan Uppal Cleveland Clinic
PB66 (#200)	Atypical Presentation of Wild-Type Transthyretin Amyloidosis: The First Reported Case in the Kidneys	Tracy Joshi Boston Medical Center
PB67 (#201)	Skull Base Amyloidosis post Heart Transplantation in a Patient with Wild Type Transthyretin Cardiac Amyloidosis	Artur Schneider Mayo Clinic
PB68 (#203)	First genome-wide association study of plasma transthyretin concentration	Mette Christoffersen Rigshospitalet
PB69 (#208)	Using cardiac troponin to predict abnormal technetium-99m pyrophosphate scans in patients with suspected transthyretin amyloidosis	Laura De Michieli Universita degli Studi di Padova
PB70 (#211)	Identifying and Tracking the Evolution of Wild-Type Transthyretin (ATTRwt) Amyloidosis in Extracardiac Tissues/Organs	Andrew Staron Boston Medical Center
PB71 (#223)	Unusual location and presentation of wild type Transthyretin Amyloidosis: A case series	Melissa Rudie OhioHealth
PB72 (#232)	Multistakeholder perspectives on challenges and solutions in the diagnosis of adult-onset rare disease: the amyloidosis paradigm	Agnes FARRUGIA AFCA
PB73 (#234)	Trends in Diagnostic Testing in Medicare Patients with Wild-Type Transthyretin Cardiac Amyloidosis	Ronald Witteles Stanford University
PB74 (#258)	Atrial Fibrillation Prevalence and Gender Disparities in Patients with Transthyretin Cardiac Amyloidosis: Insights from a Retrospective Cohort Study	Dipan Uppal Cleveland Clinic
PB75 (#297)	Screening for amyloid in patients with lumbar spinal stenosis: A single site assessment of prevalence, type, and extent of amyloid burden in the ligamentum flavum	Emily Martin University of Tennessee System
PB76 (#334)	Mistreatment with Tafamidis for Erroneous Diagnosis of ATTR Cardiac Amyloidosis: Case Series	Hilda Gonzalez The University of Alabama System
PB77 (#357)	Patient-reported Diagnostic Journey of Patients Recently Diagnosed with Transthyretin Amyloidosis: Data from the Amyloidosis Research Consortium's 2022 and 2023 Amyloidosis Community Surveys	Sabrina Rebello Amyloidosis Research Consortium
PB78 (#358)	Prevalence of hypogonadism among men with ATTR-cardiomyopathy	Hodrin Kamnang Mass General Brigham Inc
PB79 (#364)	Incidence and Clinical Characteristics of Cardiac Amyloidosis in Italy	Vincenzo Castiglione Scuola Superiore Sant'Anna
PB80 (#390)	Taste sensitivity evaluation in patients with hereditary amyloidosis associated with transthyretin (TTR) Ile127Val, in Brazil: a preliminary study	Stefania Carvalho Fundacao Bahiana para Desenvolvimento das Ciencias

TUESDAY, MAY 28, 2024 ORAL ABSTRACTS AND POSTERS

PB81 (#411)	Prevalence of Transthyretin Amyloid cardiomyopathy in patients hospitalized for heart failure with preserved ejection fraction in an Argentine center.	Santiago Decotto Hospital Italiano de Buenos Aires
PB82 (#440)	SPREAD-ATTR: evaluation of teaching amyloidosis in internships in primary health care.	Bruno Bueno Fundacao Arnaldo Vieira Carvalho
PB83 (#443)	New reference ranges of free light chain ratio: impact on clinical practice in AL and ATTRwt amyloidosis	Paolo Milani Universita degli Studi di Pavia
PB84 (#461)	Demographic and surgical characteristics of patients with and without carpal tunnel amyloidosis: a case-control study of 8816 consecutive patients.	Marc-Antoine Delbarre Republique Francaise
PB85 (#462)	Scintigraphic cardiac amyloidosis after carpal tunnel surgery: demographic, surgical and histological risk factors	Marc-Antoine Delbarre Republique Francaise
PB86 (#489)	Crystal amyloid: a simple, rapid, reliable, robust and cost-effective new screening assay for toxic misfolded transthyretin oligomers and molecular associates	Quinlan Mewborne Mayo Clinic
PB87 (#514)	Concomitant Aortic stenosis and ATTR Amyloidosis	Ricardo Torres University of Cincinnati
PB88 (#523)	Implementation Strategies To Increase The Early Detection Of Cardiac Amyloidosis	Sandesh Dev Arizona Board of Regents
PB889 (#528)	Epidemiology of Transthyretin Cardiac Amyloidosis in US Veterans from 2012 to 2021	Simar Singh Arizona Board of Regents
PB90 (#535)	Electrocardiographic findings among patients with ATTR cardiomyopathy: comparison between wild type and mutant forms in the Brazilian population – Results of the Transthyretin Cardiac Amyloidosis Registry in the state of São Paulo, Brazil (REACT/SP)	Pedro Schwartzmann Unimed Hospital - Ribeirão Preto
PB91 (#553)	Diagnosing Transthyretin Amyloidosis: A single centre experience with histopathological diagnosis	Natasha Gorrie Sisters of Charity of Australia
PB92 (#559)	Increasing clinicians' suspicion of TTR amyloidosis using a retrospective algorithm	Jessica Ammon The University of Tennessee System
PB93 (#19)	Transthyretin amyloid cardiomyopathy among patients with hypertrophic cardiomyopathy: cardiac imaging and electrocardiographic findings from the TTRACK study	Pablo Garcia-Pavia Universidad Autonoma de Madrid
PB94 (#256)	A readability analysis of online patient information for cardiac amyloidosis	Stefano Byer Iowa Board of Regents
PB95 (#343)	Unraveling Hereditary Transthyretin Mysteries: Racial and Ethnic Perspectives in Randomized Transthyretin Amyloidosis Trials	Eson Ekpo Scripps Health
PB96 (#442)	Epidemiological Characteristics of Cardiac Amyloidosis among Hawaii's Majority-Minority Population	Jonathan Hu University of Hawai'i System

TUESDAY, MAY 28, 2024 ORAL ABSTRACTS AND POSTERS

PB97 (#460)	Gender-related differences in patient reported outcomes in transthyretin amyloid cardiomyopathy: a cross-sectional study.	Dimitrios Bampatsias Columbia University
PB98 (#542)	Within 3 decades of reports on the 3 most common Transthyretin Amyloid subtypes	Kwaku Appiah-Kubi C K Tedam University of Technology and Applied Sciences

IMAGING

PB99 (#62)	Unusually seen pattern of 99mTc-DPD soft tissue uptake in a patient with AL amyloidosis. Is it an amyloid type indicator in specific cases?	Ioannis Panagiotopoulos Onaseio Kardiocheiourgiko Kentro
PB100 (#94)	Screening and profile of cardiac involvement in patients with hereditary transthyretin amyloidosis from a reference center in Brazil.	Fabio De Souza Universidade Federal do Estado do Rio de Janeiro
PB101 (#98)	Age related incidence and prognosis of incidental myocardial uptake on HDP-scintigraphy.	Tore Bach-Gansmo UiT Norges arktiske universitet
PB102 (#100)	Left ventricular myocardial work improves in response to treatment and is associated with survival among patients with light chain cardiac amyloidosis	Alexandros Briasoulis Ethniko kai Kapodistriako Panepistemio Athenon
PB103 (#111)	Reduction of 99mTc-pyrophosphate uptake in patients with ATTR cardiac amyloidosis after tafamids therapy: comparison between conventional methods and a new quantitative method (RAVAT)	Tsuneaki Yoshinaga Shinshu Daigaku
PB104 (#191)	Usefulness of scintigraphy with [99mTc]Tc-DPD for the detection of transthyretin cardiac amyloidosis. Reference center experience in endemic area.	Núria Orta Tomàs Govern de les Illes Balears
PB105 (#194)	[18F]-Florbetaben PET/CT holds prognostic value in cardiac AL amyloidosis	Giuseppe Vergaro Scuola Superiore Sant'Anna
PB106 (#197)	Imaging cardiac amyloidosis using 18F-florbetaben positron electron topography (PET) in systemic light chain (AL) amyloidosis.	Nirija Ranjit Anderson Queensland Government
PB107 (#244)	Diagnostic utility of left atrial and right ventricular strain analyses in patients with AL amyloidosis	Faizi Jamal City of Hope
PB108 (#248)	ATTR cardiomyopathy patients receiving anti-amyloid treatment may exhibit dissociation between cardiac 99mTc-Pyrophosphate uptake and cardiomyopathy progression	Marcus Simoes Govern do Estado de Sao Paulo
PB109 (#252)	Preliminary Evaluation of 99mTc-Labeled Peptide p5+14 (AT-05) for the Detection of Cardiopulmonary Amyloidosis Using SPECT/CT and Planar Gamma Scintigraphic Imaging	Jonathan Wall University of Tennessee System
PB110 (#274)	Prediction of Transthyretin Amyloid Cardiomyopathy in Heart Failure with Reduced Ejection Fraction Using the ATTR-CM Score	Daniel Davies MayoClinic
PB111 (#276)	Development of novel technetium-99m complexes as light chain amyloidosis radiodiagnostic tracers.	Efstathios Kastritis

TUESDAY, MAY 28, 2024 ORAL ABSTRACTS AND POSTERS

		Ethniko kai Kapodistriako Panepistemio Athenon
PB112 (#283)	Low Utilization of Nuclear Scintigraphy for Cardiac Amyloidosis Evaluation among Patients with Aortic Stenosis Referred for Transcatheter Aortic Valve Replacement	Firas Al Badarin Cleveland Clinic
PB113 (#290)	Omics data-derived systems biology to shed light on molecular mechanisms characterizing the heart tissue of AL λ and ATTR amyloidosis patients	Dario Di Silvestre Consiglio Nazionale delle Ricerche
PB114 (#298)	Early Development and Pre-Clinical Evaluation of a Fluorine-18 Labeled Peptide, p5+14, for the Detection of Amyloid Cardiomyopathy by PET/CT Imaging	Eric Webster University of Tennessee System
PB115 (#302)	Uptake of Iodine (124I) Evuzamitide in Patients with AL and ATTR Amyloidosis and Correlation with Echocardiographic Parameters	Robert Heidel University of Tennessee System
PB116 (#362)	Right heart dysfunction in patients with cardiac amyloidosis	Enas Ahmed Mayo Clinic
PB118 (#403)	Prevalence of moderate-severe aortic stenosis in patients with wild-type transthyretin amyloidosis in a developing country.	Santiago Decotto Hospital Italiano de Buenos Aires
PB119 (#412)	Clinical profile and outcome of cardiac amyloidosis in a middle-income country.	Marcelo Goulart Paiva Hospital 9 de Julho
PB120 (#416)	Automatic quantification of AL and ATTR amyloidosis disease burden using 124I-evuzamitide, a novel radiotracer	Zhiyang Wei Harvard University
PB121 (#418)	Wild-type Transthyretin Cardiac Amyloidosis with Positive 18F-FDG/13N-ammonia Cardiac Positron Emission Tomography	Awais Malik Mayo Clinic
PB122 (#423)	Relationship Between Myocardial Amyloid Load Measured by 124I-evuzamitide and Prognostic Staging Systems in Transthyretin Amyloid Cardiomyopathy	Morris Kim Oregon Health & Science University
PB123 (#424)	Relationship Between Myocardial 124I-evuzamitide Uptake and Extracellular Volume Fraction: A Cardiac PET/MRI Study	Morris Kim Oregon Health & Science University
PB124 (#430)	Longitudinal Contractile Diastasis: A Novel Myocardial Contraction-Relaxation Abnormality in Patients with Cardiac Amyloidosis	Osnat Itzhaki Ben Zadok Mass General Brigham Inc
PB125 (#431)	A reduced ejection fraction is associated with more severe myocardial blood flow abnormality and biomarker elevation in ATTR cardiac amyloidosis	Abdullah Azhar UPMC
PB126 (#434)	Characterizing Renal Involvement in Light Chain Amyloidosis on 124I-evuzamitide PET/MRI Imaging	Bryton Davis Oregon Health & Science University
PB127 (#435)	Utilizing 124I-evuzamitide PET/MRI to Elucidate the Relationship between Renal Dysfunction and Amyloid Deposition in Transthyretin Amyloid Cardiomyopathy	Bryton Davis

TUESDAY, MAY 28, 2024 ORAL ABSTRACTS AND POSTERS

		Oregon Health & Science University
PB128 (#445)	Cardiac Magnetic Resonance Imaging for the early diagnosis of AL cardiomyopathy: A case series	Natasha Gorrie Sisters of Charity of Australia
PB129 (#470)	Dissociation Between Scintigraphic Imaging Improvement and Lack of Clinical, Echocardiographic, and Biomarker Response in Cardiac Amyloidosis	Claudio Mesquita Universidade Federal Fluminense
PB130 (#472)	Prevalence and evolution over time of 12-lead ECG and Holter monitoring features in patients with wild-type transthyretin cardiac amyloidosis	Giuseppe Damiano Sanna Foundation IRCCS Policlinico San Matteo, Pavia (Italy)
PB131 (#477)	Diffuse soft tissue uptake and photopenic liver on DPD scintigraphy.	Tore Bach-Gansmo UiT Norges arktiske universitet
PB132 (#488)	Longitudinal Changes in Quantitative 99mTc-PYP SPECT/CT Myocardial Metrics with Transthyretin Stabilization Therapy in Transthyretin Cardiac Amyloidosis	Shilpa Vijayakumar Harvard University
PB133 (#502)	A false positive 99mTechnetium-pyrophosphate Cardiac Scintigraphy in a suspected case of cardiac amyloidosis with FLNC variant.	Mariana P Xerfan Corso Governor do Estado de Sao Paulo
PB134 (#505)	Evolution over time of echocardiographic features in patients with wild-type transthyretin cardiac amyloidosis	Giuseppe Damiano Sanna Foundation IRCCS Policlinico San Matteo, Pavia (Italy)
PB135 (#506)	Quantitative Uptake of 124I-Evuzamitide on PET Correlates with Markers of Transthyretin Cardiac Amyloidosis, Quality of Life, and Functional Status	Dia Smiley Columbia University
PB136 (#508)	Left atrial mechanical dispersion as a novel predictor biomarker of new-onset atrial arrhythmias in cardiac amyloidosis	Robert Adam Universitatea de Medicina si Farmacie Carol Davila din Bucuresti
PB137 (#512)	Lack of Temporal Change in the Yield of Tc-99m PYP scintigraphy: A single-center experience	Joseph Donohue UPMC
PB138 (#527)	Technetium Pyrophosphate Scintigraphy Ordering Provider Specialties	Valmiki Maharaj Regents of the University of Minnesota
PB139 (#530)	Incremental Value of Relative Wall Thickness in Echocardiographic Suspicion of Cardiac Amyloidosis	Michel Chedid El Helou Cleveland Clinic
PB140 (#533)	Left Ventricular Outflow Tract Obstruction in Cardiac Amyloidosis	Josh Longinow Allegheny Health Network
PB141 (#536)	Cardiac Involvement in Rare Forms of Amyloidosis Assessed Using 124I-Evuzamitide PET/CT	Olivier Clerc Mass General Brigham Inc
PB142 (#537)	Temporal Changes in Cardiac Amyloid Burden Assessed Using 124I-Evuzamitide PET/CT	Olivier Clerc Mass General Brigham Inc
PB143 (#539)	Abnormal global longitudinal strain correlates with amyloidogenic light chain-induced myocardial toxicity in patients without significant amyloid fibril deposition	Camille Edwards Boston University

TUESDAY, MAY 28, 2024 ORAL ABSTRACTS AND POSTERS

PB144 (#557)	Awareness and diagnosis of transthyretin cardiac amyloidosis in Latin America. Three years follow-up of the AMILO-LATAM research group	Isabel Carvajal Juarez Instituto Nacional de Cardiología Ignacio Chavez, Mexico
PB145 (#565)	Echocardiographic Parameters for Risk Stratification in ATTR cardiac amyloidosis	Paul Geenty The University of Sydney
PB146 (#571)	Quantification of Left Atrial Amyloid Burden in Light Chain Amyloidosis: A 18F-Florbetapir PET/CT Study	Siddharth Trivedi Harvard University

ORGAN TRANSPLANT

PB147 (#120)	Heart Transplant in Light Chain Cardiac Amyloidosis: A Single-Center Experience	Michel Chedid El Helou Cleveland Clinic
PB148 (#121)	Heart Transplant in Transthyretin Cardiac Amyloidosis: A Single-Center Experience	Michel Chedid El Helou Cleveland Clinic
PB149 (#145)	FAP-LIFE: Familial Amyloid Polyneuropathy and Long-term Impact Following Liver Transplantation: Evaluating Factors	Ilias Kounis Universite Paris-Saclay
PB150 (#325)	Transplant Associated Thrombotic Microangiopathy Post Autologous Hematopoietic Stem Cell Transplant: 2 Cases in Kidney Transplant Recipients with Relapsed AL Amyloidosis	Elena-Bianca Barbir Mayo Clinic
PB151 (#415)	Heart transplantation in amyloidosis in a developing country. Clinical and imaging manifestations.	Santiago Decotto Hospital Italiano de Buenos Aires
PB152 (#446)	Cardiac transplantation for transthyretin amyloidosis (ATTR): A single centre experience	Natasha Gorrie Sisters of Charity of Australia
PB153 (#548)	Early recurrence of myocardial amyloid deposition after heart transplantation in two family members with hereditary V40I amyloidosis	David Fermin Corewell Health
PB154 (#549)	The Quest to Treat - A Case of AA Amyloidosis Diagnosed After Kidney Transplantation	Itunu Owoyemi Cleveland Clinic
PB155 (#568)	Severe Macroglossia in a Patient with p.Val142Ile Hereditary Transthyretin Amyloidosis Manifesting 15 years After Heart Transplantation	Mazen Hanna Cleveland Clinic

WEDNESDAY, MAY 29, 2024, ORAL ABSTRACTS AND POSTERS

DIAGNOSIS ATTR

OC1 (#175)	Surprising findings of transthyretin in stenotic aortic valves	Ulrika Thelander Uppsala Universitet
OC2 (#531)	Serum neurofilament light chain levels show promise as a biomarker for early detection and diagnosis of ATTRv Amyloidosis: A meta-analysis	Kwaku Appiah-Kubi C K Tadam University of Technology and Applied Sciences
OC3 (#555)	Clinical Laboratory and Electrocardiogram Models to Screen for Transthyretin Cardiac Amyloidosis	Surendra Dasari Mayo Clinic
OC4 (#330)	Analysis of the intestinal microbiome in patients with transthyretin amyloidosis with and without cardiac involvement and its correlation with ecocardiographic parameters and biomarkers.	João Henrique Rissato Governo do Estado de Sao Paulo

PROGNOSIS AND TREATMENT OF ATTR

OC5 (#115)	High sensitivity cardiac troponin I for risk stratification in wild-type transthyretin amyloid cardiomyopathy	Laura De Michieli Universita degli Studi di Padova
OC6 (#257)	Impact of SGLT2 Inhibitors on the Incidence of Cardiac Arrhythmias and Overall Outcomes in Transthyretin Cardiac Amyloidosis	Stefano Byer Iowa Board of Regents
OC7 (#281)	Acoramidis Achieves Early Reduction in Cardiovascular Death or Hospitalization in Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Results from the ATTRIBUTE-CM Clinical Trial	Kevin Alexander Stanford University
OC8 (#136)	RV-PA uncoupling is a strong predictor of mortality in transthyretin amyloid cardiomyopathy.	Stephanie Schwarting Ludwig-Maximilians-Universitat Munchen
OC9 (#261)	The Impact of an Active Ascertainment Approach on Differences in Echocardiographic Phenotypes for Women Diagnosed with Transthyretin Cardiac Amyloidosis: The SCAN-MP Study	Frederick Ruberg Columbia University
OC10 (#282)	Treatment-related Early Increase in Serum TTR is Associated With Lower Cardiovascular Hospitalization in ATTR-CM: Insights From ATTRIBUTE-CM	Margot Davis University of Washington System
OC11 (#387)	Clinical impact of beta-blocker withdrawal in Transthyretin amyloid cardiomyopathy	Nerea Mora Ayestarán Universidad Autonoma de Madrid
OC12 (#193)	Antisense oligonucleotide therapy for familial AA amyloidosis, A N of 1 trial	Nelson Leung Mayo Clinic

PROGNOSIS/NATURAL HISTORY OTHER MORE RARE AMYLOIDOSES

OC13 (#169)	Autosomal dominant ApoA4 mutations present as tubulointerstitial kidney disease with medullary amyloidosis	Ales Hnizda Univerzita Karlova
-------------	--	-----------------------------------

WEDNESDAY, MAY 29, 2024, ORAL ABSTRACTS AND POSTERS

OC14 (#495)	Biomarker-based renal response and progression criteria in AA amyloidosis: results from the testing cohort of the Pavia-Heidelberg study	Marco Basset Regione Lombardia
OC15 (#34)	Inflammatory diseases underlying AA amyloidosis: analysis of 952 patients seen at a single reference centre over 34 years	Helen Lachmann University of London
OC16 (#408)	The fibrillogenic ApoAIV signal sequence is an excellent proteomic marker for diagnosing AApoAIV amyloidosis	Ellen Mcphail Mayo Clinic

Basic Science Other More Rare Amyloidoses

OC17 (#27)	Amyloid-collagen fibrils as potential templates for pathologic biomineralization in calcific aortic valve disease	Olga Gursky Boston University
OC18 (#155)	Interactions of variants of human apolipoprotein A-I with biopolymeric model matrices. Effect of collagen and heparin.	Maria Alejandra Tricceri Universidad Nacional de la Plata, Buenos Aires
OC19 (#350)	Investigating cross-seeding interactions of functional amyloids	Rebecca Price University of Liverpool
OC20 (#378)	Local amyloid motifs mediate tau polymorphism and cellular propagation	Nikolaos Louros University of Texas System
OC21 (#83)	Implication of serum amyloid A and apolipoprotein E polymorphism in AA amyloidosis secondary to rheumatoid arthritis	Takeshi Kuroda Niigata Daigaku, Japan

DIAGNOSIS OTHER MORE RARE AMYLOIDOSES

PC1 (#28)	Molecular modeling of apoE interactions with amyloid-beta fibrils from human brain suggests a structural basis for apolipoprotein co-deposition with amyloids	Olga Gursky Boston University
PC2 (#36)	Study of the binding of serum proteins to amyloid fibrils	Yohei Misumi Kumamoto Daigaku
PC3 (#73)	Analysis of SAA fragments digested by a lysosomal protease.	Kouhei Kawaguchi Eiken Kagaku Kabushiki Kaisha
PC4 (#84)	Cryo-EM structural characterisation of toxic protein aggregates in a cat affected by AA Amyloidosis	Melissa Milazzo Universita degli Studi di Milano
PC5 (#336)	Proteome and metabolome remodeling in <i>C. elegans</i> strains expressing different isoforms of human β 2 microglobulin	Sofia Giorgetti Universita degli Studi di Pavia
PC6 (#474)	Challenge to differentiate between localized and systemic amyloidosis: case series report	Larissa Bruscky Governo do Estado de Sao Paulo
PC7 (#173)	Optimizing MALDI-TOF for Early Detection of A-ATTRv Disease: Insights from Predictive Models and Sample Preparations	Eugenia Cisneros-Barroso Govern de les Illes Balears

WEDNESDAY, MAY 29, 2024, ORAL ABSTRACTS AND POSTERS

PC8 (#329)	High frequency of occult transthyretin and apolipoprotein A-I-type amyloid in aortic valves removed by valve replacement for aortic stenosis	Kohei Honda Panasonic Holdings Kabushiki Kaisha
PC9 (#47)	Unsuspected light chain deposition disease diagnosed by labial salivary gland biopsy	Jinghua Wang Guangdong Provincial People's Hospital
PC10 (#51)	Evaluation of adding information of amino acid modifications affected by formalin fixation on proteomic typing of amyloidosis	Mitsuki Nakao Kumamoto Daigaku
PC11 (#52)	AEFEMP1 amyloidosis: A single center experience	Masayoshi Tasaki Kumamoto Daigaku
PC12 (#123)	It's not just the heart: Hereditary transthyretin amyloid hidden in bladder cancer	Buba Marong Scripps Clinic
PC13 (#141)	Mass Spectrometry identification of 12 cases of AGLP1 (Glucagon-like peptide 1 analog) amyloidosis	Julie A Vrana Mayo Clinic
PC14 (#153)	Hereditary Amyloidosis: insights into a fibrinogen A variant diagnosis	Maria Alejandra Tricerri Universidad Nacional de la Plata
PC15 (#189)	The Amyloidosis Intersection: Exploring Dual Types in a Single Host	Lisa Mendelson Boston University
PC16 (#239)	Novel Analytic Methodology Enables Postmortem Diagnosis of Hereditary ApoA1 Amyloidosis	Karen Rech Mayo Clinic
PC17 (#240)	Triple amyloidosis: AL, AA, and wild-type ATTR in a single patient with amyloid myopathy	Santiago Martinez Sosa Mayo Clinic
PC18 (#312)	Monoclonal Gammopathy of Clinical Significance: Experience of 10 years at the University of Calgary	Victor Jimenez Zepeda Alberta Government
PC19 (#421)	Can lightning strike twice? First reported case of dual hereditary AGel and ATTRwt cardiac amyloidosis in a 49-year-old male	Jeanne Theis Mayo Clinic
PC20 (#425)	Case Report of GLP-1 Amyloidosis: The Importance of Amyloid Typing	Ellen Lewis Alberta Government
PC21 (#426)	Concomitant Diagnosis of Insulin Derived Amyloidosis (AIns) and Lymphoma: A Case Report	Ellen Lewis Alberta Government
PC22 (#427)	Dual Amyloidosis Found on Transverse Carpal Ligament Biopsy: A Case Report	Ellen Lewis Alberta Government
PC23 (#447)	Diagnostic error and the importance of cardiac biopsy in the differentiation of amyloid protein: An atypical case of APOA1 amyloidosis	Diane Xavier De Ávila Fluminense Federal University
PC24 (#452)	Clinicopathologic and Outcome Characteristics of Renal Apolipoprotein C-II Amyloidosis	Samih Nasr Mayo Clinic
PC25 (#500)	Cathepsin K and Cystatin C are Co-deposited in Amyloids of Other Types	Jason Theis Mayo Clinic
PC26 (#510)	The Pavia Amyloidosis Research and Treatment Center's 25-year experience in molecular diagnostics for hereditary amyloidoses	Mario Nuvolone Universita degli Studi di Pavia

WEDNESDAY, MAY 29, 2024, ORAL ABSTRACTS AND POSTERS

PC27 (#558)	Nodular pulmonary amyloidosis as a trigger for the diagnosis of sjogren's syndrome	Pedro Garibaldi Universidade de Sao Paulo
-------------	--	--

PATIENT REPORTED OUTCOMES/QUALITY OF LIFE

PC28 (#144)	RALTAN Study: Risk Assessment for acquired transthyretin Amyloid Neuropathy in Domino Liver Transplantation recipients	Ilias Kounis Universite Paris-Saclay
PC29 (#1)	Daily life in patients with hereditary transthyretin amyloidosis: a qualitative study.	Aina Isabel Gayá Barroso Health Research Institute of the Balearic Islands (IdISBa)
PC30 (#4)	Burden of transthyretin amyloid cardiomyopathy in treatment-naïve patients by heart failure severity: results from a large, non-interventional, real-world study	Francesco Cappelli Careggi University Hospital, Florence, Italy
PC31 (#5)	Predictors of disease burden in patients with untreated transthyretin amyloid cardiomyopathy: post hoc analysis of an international survey study	Francesco Cappelli Careggi University Hospital, Florence, Italy
PC32 (#6)	Caregiver burden by severity of patient's heart failure due to transthyretin amyloid cardiomyopathy: results from a large, non-interventional, real-world study	Francesco Cappelli Careggi University Hospital, Florence, Italy
PC33 (#7)	Predictors of burden in caregivers to patients with untreated transthyretin amyloid cardiomyopathy	Lucia Ponti University of Urbino Carlo Bo, Urbino, Italy
PC34 (#89)	Clinicopathological analyses of ATTRv amyloidosis after liver transplantation with cardiogenic cerebral embolism and subarachnoid hemorrhage	Shiori Yamakawa Kumamoto Daigaku
PC35 (#101)	Exercise Rehabilitation in Patients with Cardiac Amyloidosis, a Case study	Alexandros Briasoulis Ethniko kai Kapodistriako Panepistemio Athenon
PC36 (#106)	Health-related quality of life in hereditary transthyretin amyloidosis, a cross-sectional study	Delfina Cirelli Hospital Italiano de Buenos Aires
PC37 (#165)	Health-related quality-of-life, diagnosis and treatment experiences of AL amyloidosis patients	Solène Clavreul Myeloma Patients Europe
PC38 (#214)	Disease Burden of ATTR Amyloidosis Based on the SF-36v2® Health Survey	Vaishali Sanchorawala Boston Medical Center
PC39 (#251)	A Platform for Federated Acquisition of Health-related Quality of Life Data in Systemic Amyloidosis	Tobias Dittrich Universitat Heidelberg
PC40 (#265)	The prevalence of frailty and association with disease severity in transthyretin amyloid cardiomyopathy	Elyn Montgomery Sisters of Charity of Australia
PC41 (#284)	Health-related Quality of Life as a predictor of Heart Failure Admission and Death in Patients with Amyloidosis	Konstantinos Sideris Utah System of Higher Education
PC42 (#316)	Quality of Life of Patients with Variant and Wild-Type Transthyretin Amyloidosis	Sabrina Rebello

WEDNESDAY, MAY 29, 2024, ORAL ABSTRACTS AND POSTERS

		Amyloidosis Research Consortium
PC43 (#346)	Health-Related Quality of Life (HRQoL) in Patients With Mayo Stage IV Light Chain (AL) Amyloidosis Treated With Birtamimab Plus Standard of Care (SoC): Results From the VITAL Trial	Anita D'souza Medical College of Wisconsin
PC44 (#356)	Prevalence and outcome of coronary artery disease in cardiac amyloidosis: A retrospective Austrian multicenter study	Maria Ungericht Land Tirol
PC45 (#369)	Social Determinants of Health-Related Disparities in the Diagnosis of Transthyretin Cardiac Amyloidosis	Cindi Pankratova Pfizer Inc
PC46 (#375)	Experiences and benefits of setting up an Amyloidosis patient panel within an early phase clinical trials unit	James Rickard Richmond Research Institute
PC47 (#507)	Psychometric Validation of the Transthyretin Amyloidosis – Quality of Life (ATTR-QOL) Questionnaire	Kaitlin Lagasse UnitedHealth Group Inc
PC48 (#509)	Best Practices and Key Barriers for Amyloidosis Patient Care – a Representative Analysis of Multidisciplinary Amyloidosis Specialists, Referring Physicians, Patients, and Patient Advocacy Groups at US Specialized Amyloidosis Centers	Jose Nativi Mayo Clinic
PC49 (#521)	Bortezomib Induced Ocular Toxicities in AL Amyloidosis	Shahrier Hossain Dana-Farber Cancer Institute

PROGNOSIS ATTR

PC50 (#25)	Fifty years of experience with hereditary transthyretin amyloidosis – first report from the SveATTR registry	Jonas Wixner Umea Universitet
PC51 (#45)	Performance of prognostic staging systems for Transthyretin Cardiac Amyloidosis in the disease modifying era.	Mat Maurer Columbia University
PC52 (#71)	Role of age and QRS duration as mortality predictors in a cohort of patients with transthyretin cardiac amyloidosis (ATTR-CA)	Cristhian Vicente Espinoza Romero Governo do Estado de Sao Paulo
PC53 (#86)	Autonomic Dysfunction Severity and Cardiovascular Symptoms in ATTR Cardiac Amyloidosis: Insights from the COMPASS-31 Questionnaire	Ariel Weinsaft Columbia University
PC54 (#132)	Heart failure with preserved, mildly reduced, and reduced left ventricular ejection fraction in patients with transthyretin amyloid cardiomyopathy	Georgina Del Cisne Jadán Luzuriaga
PC55 (#137)	Clinical utility of the 6-minute walk distance in cardiac transthyretin amyloidosis	Vladimir Cejka Julius-Maximilians-Universitat Wurzburg
PC56 (#204)	Prospective, Real-World Data on the Characteristics, Treatment Patterns, and Outcomes of Patients With	Julian D. Gillmore University of London

WEDNESDAY, MAY 29, 2024, ORAL ABSTRACTS AND POSTERS

	Transthyretin Amyloidosis: Design of the MaestTRO Study	
PC57 (#216)	Baseline predictors of major adverse events for transthyretin amyloidosis cardiomyopathy patients treated and untreated with disease-modifying therapy	Karan Shahi University of Calgary
PC58 (#236)	Predictors of Developing Renal Dysfunction Following Diagnosis of Transthyretin Cardiac Amyloidosis	Malcolm McDonald Cleveland Clinic
PC59 (#237)	Clinical Relevance of NT-Pro BNP at the Time of ATTR Cardiac Amyloidosis Diagnosis	Malcolm McDonald Cleveland Clinic
PC60 (#247)	Gamma-glutamyltransferase independently predicts all-cause mortality in transthyretin cardiac amyloidosis	Alberto Aimò Fondazione Toscana Gabriele Monasterio per la Ricerca Medica e di Sanità Pubblica
PC61 (#310)	The effect of tafamidis treatment on vascular aging in patients with ATTR cardiomyopathy. An observational study	Efstathios Kastritis Ethniko kai Kapodistriako Panepistemio Athenon
PC62 (#323)	The Impact of Frailty and Cardiac Amyloid Burden on 6-minute walk distance in ATTR cardiomyopathy.	Samsam Dahir Mass General Brigham Inc
PC63 (#351)	Transthyretin derived amyloid deposits in the atrium and the aortic valve: insights from multimodality evaluations and mid-term follow up	Atsushi Okada Kokuritsu Junkankibyō Kenkyū Center
PC64 (#353)	Transthyretin amyloidosis in Greece: Outcomes and changing diagnostic patterns	Efstathios Kastritis Ethniko kai Kapodistriako Panepistemio Athenon
PC65 (#373)	A Natural History Study of Transthyretin (ATTR) Amyloidosis: Trends in Overall Survival at a U.S. Referral Center	Andrew Staron Boston Medical Center
PC66 (#381)	Left Ventricular Obstruction in Transthyretin amyloid cardiomyopathy	Nerea Mora Ayestarán Universidad Autónoma de Madrid
PC67 (#389)	Impact of upgrading to cardiac resynchronization therapy or left bundle branch pacing in patients with ATTR cardiomyopathy	Belen Peiro-Aventin Universidad Autónoma de Madrid
PC68 (#395)	Natriuretic peptides, atrial fibrillation, and survival in patients with transthyretin cardiomyopathy receiving tafamidis treatment.	Dimitrios Bampatsias Columbia University
PC69 (#398)	Incidence of pacemaker implantation and prognostic value on all-cause mortality in wild-type transthyretin amyloidosis	Jens Skov Region Midtjylland
PC70 (#400)	Incidence and prognostic implications of atrial fibrillation in wild-type transthyretin amyloidosis cardiomyopathy	Jens Skov Region Midtjylland
PC71 (#428)	Evolution of Transthyretin Amyloid Cardiomyopathy Characteristics Over a 20 Year Period: A Multicenter Study of 1,168 Patients	Ahmad Masri Oregon Health & Science University

WEDNESDAY, MAY 29, 2024, ORAL ABSTRACTS AND POSTERS

PC72 (#429)	A Multicenter Study of Real-World Outcomes of Tafamidis in Transthyretin Amyloid Cardiomyopathy	Ahmad Masri Oregon Health & Science University
PC73 (#450)	Predictors of early mortality in patients with wild-type transthyretin cardiac amyloidosis	Paolo Milani Universita degli Studi di Pavia
PC74 (#453)	Reduction in All-Cause Mortality in ATTR-CM Over a 20 year Period	Brett Sperry Saint Luke's Health System
PC75 (#478)	Transthyretin Amyloidosis: Does more than one pathogenic variant confer higher severity?	Larissa Bruscky Governo do Estado de Sao Paulo
PC76 (#487)	Can patisiran stop the progression of cardiac amyloidosis in patients with ATTRE109Q amyloidosis? Description of a monocentric experience.	Massimo Russo Universita degli Studi di Messina
PC77 (#493)	Role of Blood Biomarkers in Hereditary transthyretin amyloidosis: A Real-World Experience from a Single Center.	Massimo Russo Universita degli Studi di Messina
PC78 (#504)	Interventricular septum diameter as an echocardiographic predictor of thromboembolic events (TEEs) in patients with cardiac amyloidosis (CA) without atrial fibrillation diagnosis	Cristhian Vicente Espinoza Romero Governo do Estado de Sao Paulo
PC79 (#526)	Predictors of atrial fibrillation in Brazilian patients with transthyretin amyloidosis cardiomyopathy: Insights from the REACT registry.	Cristhian Vicente Espinoza Romero Governo do Estado de Sao Paulo
PC80 (#562)	Prevalence of frailty in a contemporary population of ATTR cardiac amyloidosis	Abigail Aronson Harvard University
PC81 (#566)	Survival in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy Over a 20-Year Period	Mazen Hanna Cleveland Clinic
PC82 (#569)	Lack of an association between baseline or follow-up transthyretin levels and all-cause mortality in ATTR cardiomyopathy patients on tafamidis	Abdullah Zoheb Azhar UPMC

PROGNOSIS/NATURAL HISTORY OTHER MORE RARE AMYLOIDOSES

PC83 (#102)	Localized light chain (AL) amyloidosis presentation, treatment, and outcomes; an observational study.	Nirija Ranjit Anderson Queensland Government
PC84 (#139)	Hereditary AA Amyloidosis Caused by a Mutation in the SAA1 Promoter. Therapeutic Follow-up.	Jakub Sikora Univerzita Karlova
PC85 (#286)	Frequency and prognostic implications of translocation (11;14) in monoclonal immunoglobulin deposition disease	Samuel Rubinstein The University of North Carolina System
PC86 (#320)	Characteristics of Leukocyte Chemotactic Factor 2 (ALect2) Amyloidosis Patients from the Amyloidosis Research Consortium's 2023 Multi-Country Amyloidosis Community Survey	Sabrina Rebello Amyloidosis Research Consortium

WEDNESDAY, MAY 29, 2024, ORAL ABSTRACTS AND POSTERS

PC87 (#386)	Risk factors associated with adverse renal outcomes in renal leukocyte chemotactic factor 2-associated amyloidosis (ALECT2)	Maria Vargas Clinic
PC88 (#471)	Unveiling Natural history of Amyloidosis in Tuberculosis: A Novel Insight Using a Non-Genetic Mice Model	Akansa Garg Indian Institute of Technology Kanpur
PC89 (#556)	Clinicopathologic and Proteomic Features of Breast Amyloidosis	Michael Keeney Mayo Clinic

TREATMENTS OF ATTR

PC90 (#2)	Tafamidis 80 mg is more likely to improve disease measures than placebo in patients with transthyretin amyloid cardiomyopathy	Mazen Hanna Cleveland Clinic
PC91 (#9)	Tafamidis efficacy among octogenarian patients in the phase 3 ATTR-ACT and ongoing long-term extension study	Pablo Garcia-Pavia Universidad Autonoma de Madrid
PC92 (#13)	Safety and efficacy of tafamidis in Chinese patients with transthyretin amyloid cardiomyopathy	Zhuang Tian Peking Union Medical College Hospital, Beijing, China
PC93 (#14)	Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy	Nicholas S Streicher Society of Jesus
PC94 (#15)	Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Variant Transthyretin Amyloid Cardiomyopathy	Nicholas S Streicher Society of Jesus
PC95 (#17)	Long-term tafamidis efficacy in patients with transthyretin amyloid cardiomyopathy by baseline left ventricular ejection fraction	Brian Drachman University of Pennsylvania Health System, Philadelphia, PA, USA
PC96 (#41)	SGLT-2- inhibitors in patients with cardiac wildtype ATTR-amyloidosis	Gina Barzen Freie Universitat Berlin
PC97 (#42)	Comparison of Combination Therapy (Tafamidis Plus Silencer) vs. Tafamidis Monotherapy in Transthyretin Amyloid Cardiomyopathy: Single Center Retrospective Cohort Study	Abdirahman Wardhere Columbia University
PC98 (#77)	Genotype vs phenotype and access to treatment in patients with hereditary transthyretin amyloidosis from a reference center in Brazil	Fabio De Souza Universidade Federal do Estado do Rio de Janeiro
PC99 (#82)	Treating Transthyretin Amyloidosis with CRISPR/Cas9 via LNP Delivery for in vivo TTR Knockdown	Emma Wang YoTech Therapeutics
PC100 (#116)	Open-label treatment data from the Swedish SveaTTR registry support the efficacy of diflunisal for hereditary transthyretin amyloidosis.	Jonas Wixner Umea Universitet
PC101 (#118)	Single Center Study of Long-Term Outcomes in ATTR-CM Patients treated with Tafamidis vs Acoramidis: Early findings at the dawn of a new era.	Dimitrios Bampatsias Columbia University

WEDNESDAY, MAY 29, 2024, ORAL ABSTRACTS AND POSTERS

PC102 (#133)	Association between Patient Characteristics and Serum Neurofilament Light Chain Level in Patients with Transthyretin-Related Amyloid Cardiomyopathy	Bryton Davis Oregon Health & Science University
PC103 (#151)	Enabling the development of serum TTR as a biomarker for treatment of ATTR amyloidosis	Julian D. Gillmore University of London
PC104 (#152)	Design and rationale for MAGNITUDE, a phase 3, randomized, placebo-controlled trial of NTLA-2001, a CRISPR-based gene editing therapy, in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM)	Mathew S. Maurer Columbia University
PC105 (#171)	Effect and Safety of Patisiran in Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy and Chronic Kidney Disease	Julien Dang CHU Bicêtre, Université Paris-Saclay, France
PC106 (#174)	Neuropathy Impairment and Nutritional Status with Eplontersen in Patients with Hereditary Transthyretin-Mediated Amyloidosis	Jonas Wixner Umea Universitet
PC107 (#10)	Survival in a real-world cohort of patients with mixed phenotype transthyretin amyloidosis treated with tafamidis: an analysis from the Transthyretin Amyloidosis Outcomes Survey	Jonas Wixner
PC108 (#176)	History of Polyneuropathy and Musculoskeletal Manifestations in Patients with Transthyretin-Mediated Amyloidosis with Cardiomyopathy in APOLLO-B	Martha Grogan Mayo Clinic
PC109 (#182)	A unified analysis of the impact of rapid TTR knockdown by RNAi therapeutics across transthyretin-mediated (ATTR) amyloidosis studies	Martha Grogan MayoClinic
PC110 (#190)	Rationale and Design of ACT-EARLY, the Acoramidis Transthyretin Amyloidosis Prevention Trial	Pablo Garcia-Pavia Universidad Autonoma de Madrid
PC111 (#196)	Arginine, as a possible amino acid for prevention of ATTR amyloidosis	Atsushi Fukunari Gakko Hojin Kyushu Bunka Gakuen
PC112 (#202)	Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy: An Exploratory Analysis of Treatment Effect in Male and Female Patients	Márcia Waddington Cruz CEPARM, University Hospital, Federal University of Rio de Janeiro
PC113 (#217)	Magnitude and timing of change in monitoring parameters for transthyretin amyloidosis cardiomyopathy patients treated and untreated with tafamidis	Karan Shahi University of Calgary
PC114 (#218)	Transthyretin amyloidosis cardiomyopathy disease staging systems for patients treated with tafamidis therapy	Karan Shahi University of Calgary
PC115 (#219)	Determinants guiding clinical decision-making for treatment initiation in transthyretin amyloidosis cardiomyopathy patients in Canada	Karan Shahi University of Calgary
PC116 (#227)	ALXN2220: targeted immune activation in patients undergoing antibody-mediated cardiac ATTR amyloid depletion	Peter Christian Kahr Neurimmune

WEDNESDAY, MAY 29, 2024, ORAL ABSTRACTS AND POSTERS

PC117 (#228)	Reduction of amyloid deposition by patisiran – Evaluation by gastroduodenal biopsy and amyloid 11C-Pittsburgh compound B PET	Shinji Masuko Shinshu Daigaku
PC118 (#230)	Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy: An Exploratory Analysis in Patients With the V30M TTR Variant and Early-Onset or Late-Onset Disease	Julian D. Gillmore University of London
PC119 (#233)	Single-center one-year outcome of Vutrisiran treatment in hereditary transthyretin amyloidosis	Helena Pernice Freie Universitat Berlin
PC120 (#241)	Racial/Ethnic Differences in Treatment Utilization for ATTR Amyloidosis	Alexandra Greatsinger Analysis Group Inc
PC121 (#245)	Safety and efficacy of levosimendan in patients with cardiac amyloidosis	Alberto Aimò Fondazione Toscana Gabriele Monasterio per la Ricerca Medica e di Sanita Pubblica
PC122 (#279)	Higher Risk of Mortality in Previously Hospitalized Patients: Insights from ATTRibute-CM	Ahmad Masri Oregon Health & Science University
PC123 (#291)	Prediction of cardiac ATTR depletion by NI006 using mechanistic PK/PD modeling	Aubin Michalon Neurimmune AG
PC124 (#292)	Treatment-related Early Increase in Serum TTR is Associated with Lower Cardiovascular Mortality in ATTR-CM: Insights from ATTRibute-CM	Amrut Ambardekar University of Colorado System
PC125 (#295)	Improved Health-Related Quality of Life in Acoramidis-Treated Patients with ATTR-CM, Demonstrated by Improvements in KCCQ Scores	Marianna Fontana University of London
PC126 (#300)	ATTRibute-CM: ITT Sensitivity Analysis and Sub-Analysis Comparing Acoramidis and Placebo in Stage 4 CKD	Steen Hvitfeldt Poulsen Region Midtjylland
PC127 (#303)	Acoramidis significantly improves NT-proBNP indices that indicate ATTR-CM disease progression and predict subsequent mortality: Insights from the ATTRibute-CM Study	Pablo Garcia-Pavia Universidad Autonoma de Madrid
PC128 (#315)	Acoramidis May Improve Cardiac Function and Promote Regression in ATTR-CM: Data From the ATTRibute-CM Cardiac Magnetic Resonance (CMR) Substudy	Yousuf Razvi University of London
PC129 (#317)	Safety of Direct Current Cardioversion Without Routine Transesophageal Echocardiography in Patients with Cardiac Amyloidosis	Osnat Itzhaki Ben Zadok Mass General Brigham Inc
PC130 (#321)	Early Increase in Serum Transthyretin Level is an Independent Predictor of Improved Survival in ATTR Cardiomyopathy: Insights From Acoramidis Phase 3 Study ATTRibute-CM	Mat Maurer Columbia University
PC131 (#344)	Arrhythmia burden and progression in ATTR-CM patients treated and untreated with tafamidis	Mannat Dhillon University of Calgary

WEDNESDAY, MAY 29, 2024, ORAL ABSTRACTS AND POSTERS

PC132 (#349)	Acoramidis Improves Clinical Outcomes in Transthyretin Amyloid Cardiomyopathy	Daniel Judge Medical University of South Carolina
PC133 (#374)	Disease progression in patients with wild-type transthyretin cardiomyopathy on treatment with tafamidis: prevalence and clinical correlates.	Giulio Sinigiani Universita degli Studi di Padova
PC134 (#396)	ATTR V30M Nephropathy: Implications of switching anti-amyloid agents	Joana Tavares Governo da Republica Portuguesa
PC135 (#399)	Early tolerance of SGLT2i therapy in patients with ATTR V30M amyloidosis: staging and scoring for a standard of care evaluation across different clinical phenotypes	João Bessa E Silva Governo da Republica Portuguesa
PC136 (#402)	Health-Related Quality of Life in Patients with Symptomatic Transthyretin Amyloid Cardiomyopathy Treated with Acoramidis: An EQ-5D Analysis From the ATTRIBUTE-CM Study	Mazen Hanna Cleveland Clinic
PC137 (#409)	SGLT2 Inhibitors for Transthyretin Amyloid Cardiomyopathy: A Propensity Score-Matched Analysis	Frederick M. Lang Columbia University
PC138 (#414)	The Amyloidosis Forum: Five Years of Progress for the Public-Private Partnership to Advance Drug Development for Amyloidosis	Kristen Hsu Amyloidosis Research Consortium
PC139 (#441)	A phase III randomized study of doxycycline and tauroursodeoxycholic acid (Doxy/TUDCA) plus standard supportive therapy versus standard supportive therapy alone in cardiac amyloidosis caused by transthyretin	Paolo Milani Universita degli Studi di Pavia
PC140 (#465)	Regression of amyloid load in subcutaneous fat tissue of hereditary transthyretin amyloidosis patients during treatment with patisiran	Hendrea Tingen Rijksuniversiteit Groningen
PC141 (#498)	Establishing amyloidosis clinics at a university hospital in the Northwest of Germany	Christoph Mronga Stadt Oldenburg
PC142 (#518)	Descriptive characteristics of patients diagnosed with transthyretin amyloidosis in the commercial and Medicare populations	Neela Kumar AstraZeneca PLC
PC143 (#519)	Clinical Trial Design of AT-02 Phase 2 Open Label Extension Study in Systemic Amyloidosis	Spencer Guthrie Attralus
PC144 (#538)	Predictors of early mortality after initiation of tafamidis therapy.	Prem Soman University of Pittsburgh
PC145 (#540)	Comparison of treatment responders versus non-responders in transthyretin amyloid cardiomyopathy	Joban Vaishnav Johns Hopkins University

TREATMENTS OF OTHER MORE RARE AMYLOIDOSES

PC146 (#199)	Potential use of Multifunctional Therapeutic Cyclodextrin-Appended Dendrimer Complex for Systemic & Localized Amyloidosis Treatment	Hirofumi Jono Kumamoto Daigaku
--------------	---	-----------------------------------

WEDNESDAY, MAY 29, 2024, ORAL ABSTRACTS AND POSTERS

PC147 (#285)	Outcomes of non-AL monoclonal gammopathies of renal significance with clone-directed therapy	Samuel Rubinstein The University of North Carolina System
PC148 (#371)	Clinical presentation and treatment of genitourinary amyloidosis: A single referral center 30-year experience	Lisa Mendelson Boston University
PC149 (#8)	Survival in real-world cohort of patients with transthyretin amyloid cardiomyopathy treated with tafamidis: an analysis from the Transthyretin Amyloidosis Outcomes Survey	Pablo Garcia-Pavia Hospital Universitario Puerta de Hierro Majadahonda



QR Code for Oral
Abstracts and Posters